Media coverage about Idera Pharmaceuticals (NASDAQ:IDRA) has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.2871936628301 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s analysis:
- Beta Factor in Focus: Idera Pharmaceuticals, Inc., (NASDAQ: IDRA) – Stock Watch (stocksnewstimes.com)
- Trading summary of overbought Mover – Idera Pharmaceuticals, Inc. (IDRA) – Wall Street Morning (wallstreetmorning.com)
- Idera Pharmaceuticals (IDRA) & Prana Biotechnology (PRAN) Head-To-Head Contrast (americanbankingnews.com)
- Idera Pharmaceuticals, Inc. (IDRA)- Stocks Sparking Bullish Stampede across Wall Street – NASDAQ Times (nasdaqtimes.com)
- Idera Pharmaceuticals, Inc. (IDRA) – Technical Deep insight – Wall Street Morning (wallstreetmorning.com)
IDRA has been the subject of a number of research analyst reports. Zacks Investment Research raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. ValuEngine raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. BidaskClub lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $4.00 target price on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $5.75.
Shares of Idera Pharmaceuticals (NASDAQ IDRA) traded down 4.33% during mid-day trading on Thursday, reaching $2.65. The company’s stock had a trading volume of 1,999,475 shares. The company’s market cap is $396.52 million. Idera Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $2.87. The company has a 50-day moving average of $2.15 and a 200-day moving average of $1.98.
Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.20 million. Equities research analysts forecast that Idera Pharmaceuticals will post ($0.48) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Idera Pharmaceuticals (IDRA) Earning Somewhat Favorable Press Coverage, Analysis Shows” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2956101/idera-pharmaceuticals-idra-earning-somewhat-favorable-press-coverage-analysis-shows.html.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.